ESC/ERS PAH Four-Strata Risk Assessment
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۰۰۰ • واحد: m
حداقل ۱ — حداکثر ۵۰۰۰۰ • واحد: ng/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- stratified≥ 0
The ESC/ERS PAH Four-Strata Risk Assessment calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include who fc. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Pulmonary arterial hypertension 4-strata risk (ESC/ERS 2022).
Clinical Indication
The ESC/ERS PAH Four-Strata Risk Assessment is indicated for bedside clinical practice to support Pulmonary arterial hypertension 4-strata risk (ESC/ERS 2022).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.
Limitations & Contraindications
In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.
Clinical Pearls & Action Plan
Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines.
Each variable scored 1-4; mean rounded to nearest stratum
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| six_mwd | float | Yes | 6-minute walk distance(m) |
| peptide_value | float | Yes | BNP or NT-proBNP value(ng/L) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| ≥ 0 | stratified | Risk stratum |
Evidence-Based References (EBM)
- Humbert M, et al. 2022 ESC/ERS Guidelines for pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731.
- Hoeper MM, et al. Mortality in pulmonary arterial hypertension: prediction by the 2022 ESC/ERS risk stratification. Eur Respir J. 2022.